A Phase 1 Study of BPI-371153 in Subjects with Advanced Solid Tumors or Relapsed/Refractory Lymphoma

A first-in-human study to evaluate the safety, tolerability and maximum tolerated dose (MTD) and establish the recommended phase 2 dose (RP2D) of BPI-371153, a PD-L1 Inhibitor, in patients with advanced solid tumors or relapsed/refractory lymphoma.

Trial Details

NCT ID
NCT05341557
Phase
PHASE1
Sponsor
Betta Pharmaceuticals Co., Ltd.
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • BPI-371153
Locations (sample)
  • Chaoyang, Beijing Municipality, China
  • Cangzhou, Hebei, China|38.31124,116.85334
  • Tianjin, Tianjin Municipality, China|39.14222,117.17667
  • Tianjin, Tianjin Municipality, China|39.14222,117.17667

Key Eligibility Criteria

  • Dose escalation phase: Age ≥18 and ≤65 years, male and female patients; Dose expansion phase: Age ≥18, male and female patients;
  • Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1;
  • Dose escalation phase: histologically or cytologically confirmed locally advanced or metastatic solid tumor patients (excluding HCC patients) or re…
  • Dose expansion phase: histologically or cytologically confirmed locally advanced or relapsed/metastatic Non-Driver Mutation NSCLC, relapsed/refract…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →